title: [The place of targeted treatments: receptor tyrosine kinase inhibitors].
abstract: Targeted biological treatments are aimed at correcting one or several abnormalities inherent to cancer cells by specifically affecting one or several identified abnormal cell mechanisms. Many signalisation pathways involve membrane receptors of the tyrosine kinase receptor family, notably the HER receptors (with, first-line, EGFR or epidermal growth factor receptor) and the VEGF receptors. These receptors can be blocked either by a monoclonal antibody directed against the ligand (i.e., bevacizumab or anti-VEGF Avastin) or against the extra-cellular segment of the receptor (i.e., cetuximab or anti-EGFR Erbitux) or by tyrosine kinase inhibitors of the intracellular segment of the receptor (i.e., gefitinib or Iressa and erlotinib or Tarceva). The preliminary studies with these new treatments in pulmonary oncology are presented.
authors.affiliation: Service d'Oncologie Médicale, CHU Avicenne, 125, route de Stalingrad, 93009 Bobigny. jeanne-marie.brechot@avc.ap-hop-paris.fr
authors.forename: J-M
authors.initials: JM
authors.lastname: Bréchot
mesh_terms: D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors
chemical_list: D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor